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Summary: There is a long and rich
history of research and control in
the field of schistosomiasis that has
resulted in major scientific and
public health accomplishments. Ex-
amples of such findings and ac-
complishments include immuno-
logic regulation in chronic
infections [1], the association of
helminth infections with Th1-regu-
lating Th2-type immune responses
[2], the critical role of interleukin-13
in fibrogenesis [3], and the de-
velopment and validation of the
‘‘dose pole’’ for determining prazi-
quantel dosages in the field [4,5].
Perhaps in part because of this
broad and successful history, those
who work on schistosomiasis come
from a wide variety of backgrounds
and interests. While such variety is
enriching to the field, it sometimes
results in diverse opinions about
which of the many research oppor-
tunities should be pursued. Such
diversity, we believe, has at times
led to a divisiveness that has
harmed overall progress in the
field. Partly in response to such
events, we have worked with as
many of those interested in schis-
tosomiasis as we could identify to
develop what we feel is a compre-
hensive and cohesive agenda for
schistosomiasis research (Image 1).
The Need for a New Research
Agenda
We did not develop such an agenda as an
attempt to work around or displace other
efforts to organize schistosomiasis-related
programs (for example, existing research or
control networks or the current agenda set
by the World Health Organization [WHO]
or the UNICEF/UNDP/World Bank/
WHO Special Programme on Research
and Training in Tropical Diseases [TDR]).
In fact, this agenda was developed with full
knowledge and input from some of these
existing programs. Nor is this agenda
a means to obtain funding or to provide
a priority listing of what kind of schistoso-
miasis research is needed to achieve given,
spelled-out objectives, although we hope
that the agenda may eventually be used to
further both of these goals. Rather, we
initiated this effort to help advance schisto-
somiasis research by enhancing cooperation
and communication among the community
of investigators interested in this neglected
tropical disease, with the eventual goal of
making stronger contributions to both bio-
medical science and public health.
Origins and Development
The possible development of a compre-
hensiveschistosomiasisresearch agendawas
first discussed in a symposium at the annual
meeting of the American Society of Trop-
ical Medicine and Hygiene in Washington,
D. C., in December 2005. This symposium
actually followed by a month a meeting of
the WHO/TDR Scientific Working Group
(SWG) on Schistosomiasis, held in Geneva
in November 2005. Both coordinators of
the current agenda participated fully in the
SWG on Schistosomiasis, and we strongly
encourage interested readers to read the
recently published proceedings from that
meeting of 63 investigators and public
health officials [6]. Following the American
Society of Tropical Medicine and Hygiene
symposium, the two of us then wrote an
initial draft based on e-mail-solicited input
received from first 22, then 110, and
eventually over 150 people in the field.
From January 2006 until now a total of
about 350 people involved in schistosomi-
asis-related work were asked by e-mail for
their input. We also presented the draft
agenda for discussion in two open fora, first
at the XIth International Congress of
Parasitology Associations in Glasgow, Scot-
land (August 2006), and then at the
American Society of Tropical Medicine
and Hygiene meeting in Atlanta, Georgia
(November 2006).
The final consensus schistosomiasis re-
searchagendaisprovidedinfullinBoxes1–
4. The agenda will hopefully be a useful
documentto thosefrom acrossthecomplete
spectrum of the schistosomiasis community,
from very basic research to focused and
effective public health intervention. We also
hope that as a result of feedback from the
community about the agenda, the docu-
ment itself will evolve over time.
How Can the Agenda Be Used?
From one perspective, the new agenda
may appear to be nothing more than an
exhaustive ‘‘laundry list’’ of every type of
study needed on schistosomiasis. The
agenda also has elements that could be
applied to almost any neglected tropical
disease. Nevertheless, almost the entire
schistosomiasis community participated in
its development, trying to make the distinct
parts fit a united whole. The agenda is not
an attempt to prioritize one discipline of
schistosomiasis research over another. We
specifically avoided doing this because it is
unlikely that any one funding agency
would be interested in programs across
the entire spectrum. In addition, we believe
that attempts to prioritize specific areas of
research from this broad agenda would
prove to be unproductive and would create
unnecessary factions. However, it may be
valuable for researchers within one are-
na—for example, vaccine development or
transmission dynamics—to use the agenda
to prioritize research needs within their
own field. It may also be useful for a group
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different sections of the agenda that fit well
together and then approach funding agen-
cies with linked components from the
agenda. For example, a group of investi-
gators who wanted to work together on
development of a new, more sensitive,
robust, field-applicable assay for active
infection could merge relevant aspects of
the agenda into a plan that spans genomics
through field testing, including community
acceptability, and then take that plan
forward to a funding agency. If the
consensus agenda is utilized in developing
the proposal, both the group of investiga-
tors and the funding agency would be
reassured that its foundation arose from
the group effort of literally hundreds of
experts in the field.
How the Agenda Will Evolve
Over Time
The agenda is not intended to be a static
document. Rather, if it is to be relevant to
the community, topics and approaches
must be added and removed as new
discoveries are made. The overarching
goal of the agenda is to be inclusive of all
those aspects of schistosomiasis-related
research that are considered by the
schistosomiasis community to be worth-
while, from both a basic scientific perspec-
tive and, obviously, in relationship to
ultimate disease and infection control.
We also hope to work with the Public
Library of Science (PLoS) to create a
schistosomiasis community portal based
upon the online functionality in the re-
cently launched PLoS ONE journal (http://
www.plosone.org/), in which readers can
annotate the literature, start discussion
threads, and upload their own editorial
commentaries. Through such an interac-
tive process of community interchange,
the new schistosomiasis research agenda
can be continually commented upon, rear-
ranged, and rewritten, as needs be.
Beyond the possibility of being used to
elicit funding for schistosomiasis research,
we hope that the process of compiling
the agenda itself will serve to unite the
Box 1. Tools and Interventions
A. Drugs
1. Optimization of treatment regimens in different transmission conditions
a. Number of doses
b. Dose intervals
2. Mechanisms of action (old and new drugs)
3. Identification of schistosome proteins/pathways that are candidates for drug
action
4. Development and testing of new drugs (e.g., orally active ozonides)
a. Development of schistosome cell lines for high-throughput screening
b. Functional expression of putative drug targets
c. RNAi analysis for the detection of target molecules
5. Assays for standardization of drug quality
6. Development and standardization of assays and markers for resistance to
praziquantel
7. Monitoring the nature and spread of drug resistance, and its effect on
schistosomes
8. Combinatorial effects of anti-schistosome therapies
a. Artemisinin-based combination therapies
b. Combinations of established anti-schistosome drugs with new drugs as
registered
9. Pharmacokinetics
a. Effects of infections and coinfections
b. Food intake
c. Intensity of infection and transmission
10. Impediments to treatment
a. Access to drugs
b. Access to other health care services
c. Access to appropriate information, education, and communication for
infected communities
11. How do real and/or perceived adverse events affect control programs?
B. Diagnostics
1. Optimization and combination of existing tools (immunological, ultrasound)
2. Assays for worm burden
a. Sensitive, specific, inexpensive, field applicable, using accessible speci-
mens
i. High prevalence areas
ii. Low prevalence areas
b. Able to distinguish active infection and successful cure
c. Investigate metabolites and other products as markers of infection
3. Tools for detection of morbidity or pre-morbidity
4. Validation of diagnostic approaches
a. Central standardization
b. Uniformity of assays among studies and control programs
5. Surveillance tools for control programs
a. Development and standardization of molecular monitoring
i. Humans
ii. Snails
b. Assessment of treatment failures
6. Sociocultural and economic factors influencing the validity of diagnostic tests
1659 adult Schistosoma mansoni worms
obtained by live surgical perfusion of an 18
year-old patient in 1970
doi:10.1371/journal.pntd.0000032.g001
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list of about 350 e-mail addresses of
people involved in schistosomiasis research
and practice has been generated through
this process. Hopefully, interactions within
this group will lead to: (1) more schistoso-
miasis-focused interdisciplinary networks;
(2) the development of standardized pro-
tocols for multicenter studies; (3) a higher
profile for schistosomiasis within the global
health community; (4) the further use of
repositories of schistosome-related materi-
als (such as http://www.schisto-resource.
org/ and http://www.afbr-bri.com/sr3/);
(5) recruitment of trainees; (6) enhanced
mentoring of junior schistosome research-
ers; and (7) assistance in enlisting outside
experts into the field of schistosomiasis
(Image 2).
Conclusion
This schistosomiasis research agenda
resulted from querying of about 350
investigators and officials who care deeply
about schistosomiasis. It reflects the
breadth and depth of their perspectives
on what is worth doing or finding out
about schistosomes, their hosts, and how
they interact. The agenda spans topics
from social science to genomics. The true
purpose of the agenda, and the process
leadinguptoit,isnottodebatewhetherone
perspective is moreimportant than another,
but to help organize the schistosome
community to move forward together.
Through such discussions and collabora-
tions, we hope to maximize the available
resources (people, funds, field sites, outside
experts, data sharing) and eventually better
publicize the need for all research on this
important disease, which in addition to
advancing global public health efforts also
has much to offer to fundamental bio-
medical knowledge. In addition, we hope
that this will be an inclusive and living
agenda. To make the latter attribute come
true we invite readers of PLoS Neglected
Tropical Diseases to annotate this preamble
and the agenda itself, to start discussion
threads based on individual components of
the agenda, and to submit electronic letters
to the editor concerning various aspects of
the agenda. In addition, through the
auspices of PLoS ONE and the community
portals it will offer by next year, we hope
that the agenda will serve as one focal point
for interactive interchange among the
schistosomiasis community, and thus pro-
vide a foundation for true collaborations
within and across the spectrum of research
to control of schistosomiasis.
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Box 1. Tools and Interventions (continued)
C. Control and implementation
1. Combined approaches to control
a. Evaluate integrated use of treatment, sanitation, water supply, mollusci-
cides, health communication, biological and environmental interven-
tions, and eventually vaccines in combinatorial ways, and their
community acceptability; develop comprehensive mathematical models
incorporating these control measures and their clinical and economic
impact
b. Evaluate integrated control programs, their efficacy and effectiveness
i. School-based
ii. Community-based
iii. Combination of school- and community-based approaches
2. Treatment of special populations
a. Use during pregnancy and lactation periods
b. Use during early childhood
3. Social aspects of control
a. Health communications/education programs
i. Evaluate combinations of content, communication means, participants
and institutional settings adapted to local conditions
ii. Perceptions, attitudes, and practices—the knowing and doing gap
b. Community involvement in control
i. Social dynamics of snail control by environmental modifications
ii. What are the incentives and disincentives at individual, household,
village, and regional levels for praziquantel treatment and snail habitat
modifications?
iii. Evaluation to improve sustainability, including areas of low
endemnicity
c. Control in health systems and inter-sectorial perspective
i. What determines the cost-effectiveness of various control measures?
ii. Enhancement of water resources development projects
iii. What determines whether control is part of an integrated program?
iv. Integration of control into community-directed treatment schemes
v. Dynamics of control as part of the broader health systems perspective
Cross-section of a Schistosoma mansoni adult
worm pair in the mesenteric venule of
a mouse; H&E stain
doi:10.1371/journal.pntd.0000032.g002
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Transmission
A. Hosts
1. Human
a. Genetic studies
b. Age effects
2. Reservoir hosts of human species
3. Snails
a. Tools to assess cercarial species, presence and release
b. Tools to identify and distinguish closely related snail species
c. Quantification and factors affecting absolute density of infected snails
d. Surveillance of immigrant snails into new areas
e. Assessment of genetic inbreeding on parasite transmission
f. Consequences of parasite coinfections in snails
g. Environmental impacts on parasite transmission to snails
h. Evaluation of new molluscicides
4. Genetic studies on host–parasite strain interactions and compatibility,
including genomics, mathematical models, and population structure
5. Comparison of field versus laboratory parasite isolates
B. Fresh water
1. Positive/negative effects of pollution on snails and transmission
2. Impact of environmental change (dams, irrigation projects, etc.)
3. Development, implementation, use, and impact of appropriate technologies
for water supplies
4. Environmental impact and effectiveness of molluscicide-based control
5. Impact of natural and exotic species on snails and on transmission
C. Transmission dynamics (including mathematical models)
1. Human
2. Natural, non-human hosts
3. Urban transmission
4. Low transmission areas after control programs
5. Social determinants of exposure (gender, ethnicity, occupation, migration)
6. Perceptions, attitudes, and practices—relationship to changes in transmission
D. Public awareness
1. Campaigns based on realistic DALYs (disability-adjusted life years) and impact
of schistosomiasis to increase awareness and need (public, celebrity,
politically based; at the local, national, regional, and international levels)
E. Application of geographic information systems/remote sensing and ground
verification
1. Transmission patterns and predictions
2. Geo-spatial (micro) determinants of risk
Policy Platform
PLoS Neglected Tropical Diseases | www.plosntds.org 4 2007 | Volume 1 | Issue 3 | e32Box 3. Disease Burden and Epidemiology
A. Morbidity
1. Attributable fraction
a. Anemia and mechanisms of anemia
b. Under-nutrition
c. Organ dysfunction
d. Cognitive development
e. Economic costs of infection
2. Adapt standardized tools for quality of life assessment to schistosomiasis
3. Accurate disability weights, recalibration of DALYs
4. Impact of disease on households, communities, and societies
5. Carcinogenesis (with a focus on Schistosoma haematobium and possibly S.
japonicum)
6. Effect of treatment on control of:
a. Established morbidity (e.g., organomegaly, gynecological lesions, ane-
mia, etc.)
b. Morbidity following reinfection
7. Effects on reproductive health and fertility (male and female)
8. Effects of host genetics
B. Comorbidities
1. Interactions of other infections with schistosomiasis (HIV, malaria, hepatitis B
and C, soil-transmitted helminths)
a. Effects of schistosomiasis and its treatment on coinfections
b. Effects of coinfections and their treatment on schistosomiasis
c. Effects of schistosomiasis on transmission of coinfections
2. Interactions and impact of dual schistosome infections (S. mansoni and S.
haematobium)
3. Interactions of schistosomiasis with noninfectious conditions (malnutrition,
alcoholism, autoimmunity)
4. Effects of schistosomiasis on vaccination programs
C. Pregnancy
1. Influence on child
a. Morbidity
i. In child in utero (e.g., low birth weight)
ii. In child subsequently infected
b. Immunology
i. Effect on neonatal vaccinations
ii. If child subsequently infected
2. Treatment issues
a. Need retrospective and prospective studies
b. Implementation, policy changes
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A. Vaccines
1. Discovery
a. Antigens and protective responses in model and human systems
b. High-throughput vaccine design
c. Effects on infected or previously treated hosts (protective, pathologic,
integration of vaccination with chemotherapy)
d. Vaccine types other than prophylactic (therapeutic, anti-fecundity)
e. Scale-up production (good laboratory/manufacturing practices)
f. Adjuvants/delivery (DNA versus prime boost versus protein)
2. Evaluation
a. Model systems
i. Closer look at animals that develop ‘‘sterile immunity’’
ii. Rapid assessment of vaccine efficacy
iii. Non-human primates (interface of screening and clinical trials)
b. In the field (trial design, locales, end-points, interaction with other
infections/vaccines, effect of prenatal exposures)
B. Immunology and pathology
1. During infection (human and model systems)
a. Resistance versus susceptibility—mechanisms
b. Immunopathologic mechanisms
i. Fibrosis
ii. Angiogenesis
c. Immunoregulatory mechanisms
d. Host responses to defined antigens
e. Immune evasion
f. Effects on non-immune systems (e.g., hematologic, coagulation, phar-
macologic)
2. Effects on immune response system
a. Innate immune alterations/identification of schistosome pathogen-
associated molecular patterns
b. Atopic allergy/role of schistosomiasis in ‘‘hygiene hypothesis’’
c. Autoimmune diseases
d. Schistosome molecules as adjuvants
3. Role of host genetic polymorphisms (resistance and morbidity)
4. Effect of treatment on immune responses
5. Snail responses to infection
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C. Genomes and postgenomics (of parasite life-cycle forms and snail species; in
situ and ex vivo)
1. Sequencing, annotation, database development
2. Comparisons of species and strains
3. Proteomics
4. Glycomics
D. Basic biology of life-cycle stages
1. As themselves
a. Male–female interactions
b. Female reproductive development and fecundity
2. As model systems
a. Life-cycle stage shifts as developmental biology
b. Establishment of laboratory life cycles of S. haematobium
c. Expanded studies on experimental S. japonicum
3. Fecundity and egg excretion
4. Investigation of schistosome germ cells
5. Host–parasite interactions
a. Role of host molecules in parasite development and life cycle
b. Identification of parasite molecules that regulate host function
6. Neurobiology and neuromuscular physiology
E. Biochemistry and molecular studies
1. Membrane biology
2. Metabolism using genomics, glycomics, and proteomics
3. Characterization and functional roles and uses of schistosome components
4. Development of ‘‘molecular tool box’’ for schistosomes
a. Schistosome cell lines
b. RNAi and other gene silencing tools
c. Transient and stable transgenic schistosome cells or parasites
d. Expression of schistosome proteins in other eukaryotic systems
5. Important functional genes
a. Isolate/investigate individual schistosome organs (e.g., ovary) or cells
b. Factors dictating host specificity in vertebrates and snails
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